Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NEKTAR THERAPEUTICSNKTR · Entity 4364 | Chief R&D Officer | August 18, 2026 | August 20, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NEKTAR THERAPEUTICS
Report date August 18, 2026 · Filed August 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 9,570 |
Reported balance
After 2026-08-18 transaction · row 1
1 source rowRow 1 · 2026-08-18 · Sale · Disposed 186 · Balance 9,570 F1: Represents the number of shares sold by the reporting person to cover required tax withholding obligations in connection with the vesting of the RSUs held by the reporting person and does not represent a discretionary trade by the reporting person. F2: This transaction was executed in multiple trades at prices ranging from $71.78 to $72.49. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares sold by the reporting person to cover required tax withholding obligations in connection with the vesting of the RSUs held by the reporting person and does not represent a discretionary trade by the reporting person.
F2: This transaction was executed in multiple trades at prices ranging from $71.78 to $72.49. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 18, 2020 Filed Dec 22, 2020 23:53 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantStock Option · Derivative | 71,500 | $0.00 Strike: $18.75 | $0.00 |
DisclosureSEC source: 0001209191-20-064918 · doc4.xml · derivative · entry 2 Zalevsky Jonathan · CIK 0001789857 · Chief R&D Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,500 Underlying: Common Stock · 71,500 shares Expires 2028-12-17 F2 · derivative.exercise_date: This stock option vests over four years in equal monthly installments based on continued service. Read SEC document |
| December 18, 2020 Filed Dec 22, 2020 23:53 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantCommon Stock | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-064918 · doc4.xml · nonDerivative · entry 1 Zalevsky Jonathan · CIK 0001789857 · Chief R&D Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 290,317 F1 · security: This stock award was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive, upon vesting of the unit, one share of the issuer's common stock. These RSUs vest over three years in substantially equal quarterly installments based on continued service. Read SEC document |
| November 23, 2020 Filed Nov 25, 2020 23:09 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 16,380 | $16.40 | $268,632.00 |
DisclosureSEC source: 0001209191-20-060584 · doc4.xml · nonDerivative · entry 1 Zalevsky Jonathan · CIK 0001789857 · Chief R&D Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,317 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $16.23 to $16.69. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document |
| November 16, 2020 Filed Nov 19, 2020 00:08 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 29,618 | $16.93 | $501,432.74 |
DisclosureSEC source: 0001209191-20-059247 · doc4.xml · nonDerivative · entry 1 Zalevsky Jonathan · CIK 0001789857 · Chief R&D Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 266,697 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $16.71 to $17.46. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document |
| August 17, 2020 Filed Aug 19, 2020 22:41 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 26,200 | $19.67 | $515,354.00 |
DisclosureSEC source: 0001209191-20-047620 · doc4.xml · nonDerivative · entry 1 Zalevsky Jonathan · CIK 0001789857 · Chief R&D Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 296,315 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $19.35 to $19.86. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document |
| May 18, 2020 Filed May 20, 2020 22:33 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 4,558 | $22.51 | $102,600.58 |
DisclosureSEC source: 0001209191-20-031018 · doc4.xml · nonDerivative · entry 1 Zalevsky Jonathan · CIK 0001789857 · Chief R&D Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 322,515 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $22.29 to $22.76. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document |
| February 18, 2020 Filed Feb 20, 2020 23:39 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 4,774 | $22.35 | $106,698.90 |
DisclosureSEC source: 0001209191-20-011263 · doc4.xml · nonDerivative · entry 1 Zalevsky Jonathan · CIK 0001789857 · Chief R&D Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 327,073 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $22.00 to $23.08. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document |
| December 12, 2019 Filed Dec 17, 2019 02:37 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantStock Option · Derivative | 20,100 | $0.00 Strike: $21.79 | $0.00 |
DisclosureSEC source: 0001209191-19-060790 · doc4.xml · derivative · entry 3 Zalevsky Jonathan · CIK 0001789857 · Chief R&D Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,100 Underlying: Common Stock · 20,100 shares Expires 2017-12-11 F2 · derivative.exercise_date: This stock option vests over four years in equal monthly installments based on continued service. Read SEC document |
| December 12, 2019 Filed Dec 17, 2019 02:37 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantStock Option · Derivative | 71,550 | $0.00 Strike: $21.79 | $0.00 |
DisclosureSEC source: 0001209191-19-060790 · doc4.xml · derivative · entry 2 Zalevsky Jonathan · CIK 0001789857 · Chief R&D Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,550 Underlying: Common Stock · 71,550 shares Expires 2027-12-11 F2 · derivative.exercise_date: This stock option vests over four years in equal monthly installments based on continued service. Read SEC document |
| December 12, 2019 Filed Dec 17, 2019 02:37 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantCommon Stock | 40,150 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-060790 · doc4.xml · nonDerivative · entry 1 Zalevsky Jonathan · CIK 0001789857 · Chief R&D Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 331,847 F1 · security: This stock award was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive, upon vesting of the unit, one share of the issuer's common stock. These RSUs vest over three years in substantially equal quarterly installments based on continued service. Read SEC document |
| November 18, 2019 Filed Nov 21, 2019 00:07 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 3,960 | $17.97 | $71,161.20 |
DisclosureSEC source: 0001209191-19-057492 · doc4.xml · nonDerivative · entry 1 Zalevsky Jonathan · CIK 0001789857 · Chief R&D Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 291,697 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $17.56 to $19.65. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document |
| October 01, 2019 Filed Oct 2, 2019 23:30 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantStock Option · Derivative | 150,000 | $0.00 Strike: $18.43 | $0.00 |
DisclosureSEC source: 0000899243-19-024777 · doc4.xml · derivative · entry 2 Zalevsky Jonathan · CIK 0001789857 · Chief R&D Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2027-09-30 F2 · derivative.exercise_date: This stock option vests over four years in equal monthly installments based on continued service. Read SEC document |
| October 01, 2019 Filed Oct 2, 2019 23:30 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantCommon Stock | 75,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-024777 · doc4.xml · nonDerivative · entry 1 Zalevsky Jonathan · CIK 0001789857 · Chief R&D Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 295,657 F1 · security: This stock award was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive, upon vesting of the unit, one share of the issuer's common stock. These RSUs vest over three years in substantially equal quarterly installments based on continued service. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.